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b r i e f c o m m u n i c a t i o n s
Both NRAS mutations affected amino acid residues highly conserved among RAS orthologs and paralogs ( Fig. 1c and data not shown). Gly60 is located in the switch II region. A germline KRAS mutation affecting Gly60 (G60R) had previously been reported in cardio-facio-cutaneous syndrome 8 , and the somatic NRAS mutation G60E rarely occurs in malignancies (COSMIC database; see URLs below). Alterations of the neighboring Gln61 are frequent among oncogenic RAS alterations and are known to confer impaired GTPase function. In contrast, no somatic or germline RAS gene mutation affecting Thr50 has been described so far. Thr50 is an exposed residue located in the β2-β3 loop connecting the two switch regions (Fig. 1b) but is not predicted to be directly involved in GTP and GDP binding, GTP hydrolysis, or effector interaction (Supplementary Fig. 3) .
To elucidate the consequences of the Noonan syndrome-causing NRAS mutations on protein function and intracellular signaling, we expressed each mutant as yellow fluorescent protein-NRAS fusion proteins in cells from the COS-7 line, and their functional properties in vitro were compared with wild-type NRAS and the oncogenic NRAS substitution G12V, where the latter is known to be GAP resistant and to promote constitutive activation of MAPK signaling. Expression of the NRAS substitutions T50I or G60E resulted in enhanced phosphorylation of MEK and ERK in the presence of serum or after epidermal growth factor (EGF) stimulation but, in contrast with the G12V NRAS substitution, had only marginal effects on signaling in starved cells (Fig. 2a-c) . Of note, the G60E NRAS mutant, much like G12V, accumulated constitutively in the active, GTP-bound form and appeared resistant to GAP stimulation. In contrast, the T50I NRAS mutant was not enriched in the GTP-bound state (Fig. 2d,e) , indicating a different mechanism of functional dysregulation. Biochemical characterization of this alteration provided evidence that the T50I substitution does not substantially affect intrinsic GTPase activity, GAP association or GAP-stimulated hydrolysis. Similarly, no change was observed in guanine nucleotide exchange factor-catalyzed nucleotide release, effector association or allosteric activation of SOS1 ( Supplementary Fig. 4 ).
To explore further the structural and functional consequences of the T50I change, we determined the crystal structure of the RAS mutant bound to Gpp(NH)p (an analog of GTP), but no substantial structural rearrangements were observed (Supplementary Table 2 and Supplementary Fig. 5 ). Molecular dynamics simulations of wild-type RAS indicated that Thr50 directly interacts with the polar heads of membrane phospholipids and is an integral part of a recently described functional region that controls RAS membrane orientation and signal output (Supplementary Fig. 6 ) 9 . According to this model, aside from the conformational changes involving the switch I and II regions, GTP loading of membrane-anchored RAS is predicted to rearrange a distinct region of the GTPase (comprising the β2-β3 loop and helix α5) (Fig. 1c,d ). This, in turn, would lead to a differential engagement of the C-terminal hypervariable region and helix α4 with the membrane, ultimately altering the orientation of the entire G domain of RAS with respect to the membrane. Residues Asp47 and Glu49 have been shown to be directly involved in Orange boxes on top of the alignment mark amino acids comprising the switch I and II regions, and the yellow box marks the four amino acids of the β2−β3 loop. Red dotted lines in panels a to c indicate the positions of nucleotides and amino acids, respectively, affected by Noonan syndrome-causing mutations.
Anti-pAKT
Anti-pAKT . Expression of each of the three NRAS mutants (G12V, G60E and T50I) resulted in enhanced MEK and ERK phosphorylation in the presence of serum, whereas only the oncogenic G12V substitution substantially stimulated phosphorylation of MEK and ERK in serum-deprived cells. Contrasting with what was observed for the G12V change, no effect on AKT phosphorylation was detectable in cells expressing the Noonan syndrome-causing T50I or G60E mutant under both culture conditions. Asterisk beside the pAKT blot marks artifactual bands (supplementary fig. 7 ). Total amounts of MEK, ERK and AKT in cell lysates are shown for equal protein expression and loading. (c) EGF stimulation of serum-starved cells reproduced the effects on ERK phosphorylation observed in the presence of serum. (d) Determination of GTP-bound NRAS levels in COS-7 cells transiently expressing wild-type NRAS or each mutant in the presence of serum. Similar to the oncogenic G12V mutant, G60E, but not T50I, accumulated in the GTP-bound form. (e) The same experiment was performed under serum-free conditions. Both the G12V and G60E mutants were predominantly present in the active GTP-bound form, whereas the T50I mutant was not. Addition of purified RasGAP left GTP-bound levels of the G12V and G60E mutants unaffected, demonstrating GAP resistance of these mutants, in contrast to the T50I mutant. Total amounts of exogenous (yellow fluorescent protein-tagged) NRAS in cell lysates are shown for each experiment (a-e). Specificity of the antibody employed in each experiment is indicated below each panel. Wt, wild type.
the intermolecular binding network controlling RAS membrane orientation, and their substitution was found to enhance downstream signaling through GTP-bound RAS, presumably by keeping the GTPase in a more signaling-competent orientation 9 . Consistent with this model, the RASbinding domain of RAF1 is able to recognize the relative membrane orientation of GTP-bound RAS, which is functionally translated into different signaling outputs 9 . Based on this model, we hypothesize that the T50I substitution might alter RAS orientation in a fashion similar to that documented for the D47A and E49A substitutions 9 ( Supplementary  Fig. 6 ), bolstering the interaction of GTP-bound RAS with its effectors. This proposed mechanism would explain the enhanced signal flow through the MAPK cascade in the absence of any substantial accumulation of the T50I NRAS substitution in its GTP-bound form (Fig. 2) . Taken together, these findings support the idea that Noonan syndrome-causing NRAS mutants are weak hypermorphs. Although the G60E NRAS substitution accumulates in its GTP-bound form to mimic the consequences of oncogenic substitutions affecting Gly12 or Gly13, the weakened effector binding of this mutant might account for its damped downstream effect compared to the oncogenic G12V alteration.
Here we reported that Noonan syndrome can be caused by altered signaling through NRAS. Similar to what has been observed for germline KRAS mutations causing Noonan syndrome and cardiofacio-cutaneous syndrome, germline NRAS alterations do not affect residues commonly mutated in human cancers and appear to be less activating in dysregulating intracellular signaling in vitro compared with cancer-associated somatic mutations. Considering the large size of the cohorts of affected individuals included in this study, germline NRAS mutations are estimated to be substantially less frequent than those affecting KRAS or HRAS 7 . Although we favor the hypothesis that NRAS mutations rarely occur as germline defects because of their severe consequences on embryonic and fetal development, we cannot exclude the possibility that mutations other than those described here may cause phenotypes not recognized as Noonan syndrome or related disorders. Notably, Oliveira and colleagues reported on an individual with a germline NRAS missense change (G13D) and an autoimmune lymphoproliferative disorder, without any signs of Noonan syndrome 10 . Although their observation has not been replicated so far, their findings could be consistent with the occurrence of non-overlapping allele-specific phenotypic effects resulting from different NRAS mutations than those described here.
The identification of activating NRAS mutations in Noonan syndrome provides evidence for an obligate dependency on proper function of this small GTPase in human development and growth. Even though functional redundancy among RAS proteins does exist, biological differences in these proteins are also well documented 11, 12 . Recent evidence gathered from mouse models demonstrated that these GTPases play distinct roles in development. Although loss of Kras isoforms is lethal at the embryonic stage, disruption of mouse Hras and Nras does not meaningfully perturb development. Consistently, it has been documented that RAS proteins generate distinct signal outputs despite their interaction with a shared set of activators and effectors 11, 12 , and preferential associations between specific human cancers and individual RAS genes have also been established (see COSMIC database). These and recent findings regarding Noonan syndrome and related disorders extend this concept to germline mutations and human development, showing that distinct clusters of activating mutations in the three RAS genes underlie a group of clinically related mendelian traits. Notably, whereas a small number of mutations in HRAS and NRAS underlie, respectively, Costello syndrome (MIM218040) and Noonan syndrome, a more diverse set of missense changes in KRAS results in a markedly broad phenotypic continuum 13 . Further studies are required to understand such genotype-phenotype correlations. The localization of RAS isoforms to distinct signaling nanoclusters and their ability to differentially activate canonical and non-canonical pathways, rather than distinct tissue-or cell-specific expression patterns, are believed to underlie the functional diversity of these GTPases 11, 12, 14 . Accordingly, phenotypic differences between Noonan, cardio-facio-cutaneous and Costello syndromes might be ascribed to different developmental consequences strictly depending upon these mechanisms, although the obvious similarities of these disorders testify that there are important functions in developmental programs that are shared by all members of this family of GTPases.
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